AL Amyloidosis (Amyloidosis Antibody Light). Part 2-Epidemiology, Clinical Symptoms, Diagnosis and Treatment of Amyloidosis AL

被引:0
|
作者
Usnarska-Zubkiewicz, Lidia [1 ]
Holojda, Jadwiga [2 ]
Kuliczkowski, Kazimierz [1 ]
机构
[1] Wroclaw Med Univ, Dept Hematol Blood Neoplasms & Bone Marrow Transp, PL-50367 Wroclaw, Poland
[2] Dist Specialist Hosp Legnica, Dept Hematol, Legnica, Poland
来源
关键词
amyloidosis AL; epidemiology; clinical symptoms; diagnosis; treatment; PRIMARY SYSTEMIC AMYLOIDOSIS; STEM-CELL TRANSPLANTATION; HIGH-DOSE DEXAMETHASONE; CARDIAC AMYLOIDOSIS; CHAIN AMYLOIDOSIS; MELPHALAN; COMBINATION; BORTEZOMIB; EFFICACY; TRIAL;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Studies have shown that 10-20% of patients with multiple myeloma develop AL amyloidosis. AL amyloidosis can affect the kidney and the heart, as well as cause peripheral polyneuropathy and CNS impairment. The main diagnostic test to confirm amyloidosis is the staining of the adipose tissue from abdominal fat with Congo red, which demonstrates green birefringence when polarized light is used, or reveals nonbranching fibril structures with a diameter of 10 nm under an electron microscope. Oral melphalan and prednisone have been the leading drugs in the therapy of AL amyloidosis for 30 years. The patients qualified for megachemotherapy and stem cells transplantation had to be free from severe, burdening diseases and had to have less than three involved organs (Adv Clin Exp Med 2011, 20, 6, 771-788).
引用
收藏
页码:771 / 778
页数:8
相关论文
共 50 条
  • [41] Protein and host factors implicated in the pathogenesis of light chain amyloidosis (AL amyloidosis)
    Solomon, A
    Weiss, DT
    [J]. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 1995, 2 (04): : 269 - 279
  • [42] TREATMENT OF AL AMYLOIDOSIS WITHOUT MYELOMA
    LEVY, Y
    BELGHITIDEPREZ, D
    SOBEL, A
    [J]. ANNALES DE MEDECINE INTERNE, 1988, 139 (03): : 190 - 193
  • [43] AL Amyloidosis in Myeloma: Red Flag Symptoms
    Mendelson, Lisa
    Shelton, Anthony
    Brauneis, Dina
    Sanchorawala, Vaishali
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (11): : 777 - 778
  • [44] Prospects for effective treatment of AL amyloidosis?
    Iggo, N
    Littlewood, T
    Winearls, CG
    [J]. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2000, 93 (05) : 257 - 260
  • [45] Treatment of AL amyloidosis, current data
    Jaccard, A.
    [J]. REVUE DE MEDECINE INTERNE, 2006, 27 (11): : 809 - 812
  • [46] Treatment of al amyloidosis guided by biomarkers
    Palladini, G.
    Nuvolone, M.
    Russo, P.
    Lavatelli, F.
    Perfetti, V.
    Obici, L.
    Merlini, G.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 199 - 199
  • [47] Future Developments in the Treatment of AL Amyloidosis
    Theodorakakou, Foteini
    Fotiou, Despina
    Dimopoulos, Meletios A.
    Kastritis, Efstathios
    Carbone, Antonino
    [J]. HEMATO, 2022, 3 (01): : 131 - 152
  • [48] AL amyloidosis: advances in diagnostics and treatment
    Rysava, Romana
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 (09) : 1460 - +
  • [49] Venetoclax For The Treatment of Translocation AL Amyloidosis
    Sidiqi, M. Hasib
    Al Saleh, Abdullah S.
    Leung, Nelson
    Aljama, Mohammed
    Jevremovic, Dragan
    Gonsalves, Wilson
    Buadi, Francis
    Kourelis, Taxiarchis
    Warsame, Rahma
    Muchtar, Eli
    Hobbs, Miriam
    Lacy, Martha
    Dingli, David
    Go, Ronald
    Hayman, Suzanne
    Rajkumar, S. Vincent
    Kumar, Shaji
    Dispenzieri, Angela
    Fonseca, Rafael
    Gertz, Morie A.
    Kapoor, Prashant
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E332 - E332
  • [50] COLCHICINE IN THE TREATMENT OF AA AND AL AMYLOIDOSIS
    LIVNEH, A
    ZEMER, D
    LANGEVITZ, P
    SHEMER, J
    SOHAR, E
    PRAS, M
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 1993, 23 (03) : 206 - 214